000840339 001__ 840339
000840339 005__ 20220930130137.0
000840339 0247_ $$2doi$$a10.1002/jlcr.3578
000840339 0247_ $$2ISSN$$a0022-2135
000840339 0247_ $$2ISSN$$a0362-4803
000840339 0247_ $$2ISSN$$a1099-1344
000840339 0247_ $$2pmid$$apmid:29110328
000840339 0247_ $$2WOS$$aWOS:000428647600003
000840339 037__ $$aFZJ-2017-07881
000840339 041__ $$aEnglish
000840339 082__ $$a540
000840339 1001_ $$0P:(DE-Juel1)131849$$aSpahn, Ingo$$b0
000840339 245__ $$aDevelopment of novel radionuclides for medical applications 
000840339 260__ $$aNew York, NY [u.a.]$$bWiley$$c2018
000840339 3367_ $$2DRIVER$$aarticle
000840339 3367_ $$2DataCite$$aOutput Types/Journal article
000840339 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1526461727_22448
000840339 3367_ $$2BibTeX$$aARTICLE
000840339 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000840339 3367_ $$00$$2EndNote$$aJournal Article
000840339 520__ $$aMedical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to non-standard positron emitters (e.g. 64Cu, 86Y, 124I, 73Se) and novel therapeutic radionuclides emitting low-range β- particles (e. g. 67Cu, 186Re), conversion or Auger electrons (e.g. 117mSn, 77Br) and α-particles (e.g. 225Ac). A brief account of various aspects of development work (i.e. nuclear data, targetry, chemical processing, quality control) is given. For each radionuclide under consideration the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.
000840339 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000840339 588__ $$aDataset connected to CrossRef
000840339 7001_ $$0P:(DE-Juel1)131840$$aQaim, Syed M.$$b1$$eCorresponding author
000840339 773__ $$0PERI:(DE-600)1491841-9$$a10.1002/jlcr.3578$$p126-140$$tJournal of labelled compounds and radiopharmaceuticals$$v61$$x0362-4803$$y2018
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.pdf$$yRestricted
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.gif?subformat=icon$$xicon$$yRestricted
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.jpg?subformat=icon-180$$xicon-180$$yRestricted
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.jpg?subformat=icon-640$$xicon-640$$yRestricted
000840339 8564_ $$uhttps://juser.fz-juelich.de/record/840339/files/Qaim_et_al-2018-Journal_of_Labelled_Compounds_and_Radiopharmaceuticals.pdf?subformat=pdfa$$xpdfa$$yRestricted
000840339 8767_ $$8BPL00524/17$$92017-11-28$$d2017-11-28$$eReprint$$jBestellt$$zUSD 1350,- , 50 Reprints
000840339 909CO $$ooai:juser.fz-juelich.de:840339$$pVDB$$popenCost
000840339 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131849$$aForschungszentrum Jülich$$b0$$kFZJ
000840339 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131840$$aForschungszentrum Jülich$$b1$$kFZJ
000840339 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000840339 9141_ $$y2018
000840339 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000840339 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ LABELLED COMPD RAD : 2015
000840339 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000840339 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000840339 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000840339 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000840339 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000840339 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000840339 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000840339 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000840339 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000840339 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000840339 920__ $$lyes
000840339 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000840339 980__ $$ajournal
000840339 980__ $$aVDB
000840339 980__ $$aI:(DE-Juel1)INM-5-20090406
000840339 980__ $$aAPC
000840339 980__ $$aUNRESTRICTED
000840339 9801_ $$aAPC